XELOX combined with Fruquintinib and Sintilimab
Fission
Phase 2 small_molecule active
Quick answer
XELOX combined with Fruquintinib and Sintilimab for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active